Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Clin (Barc). 2004 Oct 23;123(14):535-7.

[Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus].

[Article in Spanish]

Author information

  • 1Sección de Endocrinología y Nutrición, Hospital Universitario Morales Meseguer, Murcia, Spain. mariaf.illan@carm.es

Abstract

BACKGROUND AND OBJECTIVE:

Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease. The levels of C-reactive protein (CRP), the prototypic marker of inflammation, are associated with an increased risk for cardiovascular events. The statins have direct anti-inflammatory effects. Thus, we tested the effects of atorvastatin on levels of CRP on patients with type 2 diabetes.

PATIENTS AND METHOD:

We evaluated CRP in baseline and 6 months after onset of 20 mg daily atorvastatin therapy of 30 patients with type 2 diabetes with hyperlipidemia. Clinical and biochemical data were obtained.

RESULTS:

CRP-levels were significantly decreased after treatment with atorvastatin compared with baseline (median change: -4,99 mg/l; p < 0.001). We observed an correlation between CRP baseline with body mass index (r = 0.429; p = 0.018), serum fibrinogen (r = 0.607; p = 0.001) and microalbuminuria (r = 0.470; p = 0.01). Conversely, there was no significant correlation between CRP baseline with LDL cholesterol. The CRP reduction was significantly correlated with fasting glucose (r = -0.457; p = 0.019) and glycosylated hemoglobin at 6 months (r = -0.421; p = 0.03).

CONCLUSIONS:

These results confirm findings from previous studies that atorvastatin reduce CRP levels in a largely LDL cholesterol independent manner.

PMID:
15535926
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ediciones Doyma, S.L.
    Loading ...
    Write to the Help Desk